Is Chromadex Corp. overvalued or undervalued?

As of 15 October 2023, Chromadex Corp. has moved from fair to attractive based on recent evaluations. The company appears to be undervalued at this time. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-book (P/B) ratio of 1.8, and a debt-to-equity (D/E) ratio of 0.5, indicating a solid financial position relative to its earnings and assets.
In comparison to its peers, such as Herbalife Nutrition Ltd. with a P/E of 18.5 and Amgen Inc. at a P/E of 16.0, Chromadex's lower valuation suggests it may be trading at a discount. Additionally, the company has shown resilience in its stock performance, with recent returns outpacing the Sensex, reinforcing the notion that it is undervalued in the current market.